Join the Action Alerts PLUS Community today!
Stock futures lower heading into 'quadruple witching hour'; FDA panel debates COVID boosters; U.S. Steel updates on profits and China Evergrande's debt woes have investors asking if it's 'too big to fail'.
Real Money's Tim Cook has spotted a key pattern in the newly public company's trading.
Drug maker AbCellera wins emergency use authorization for COVID treatment.
'Lilium won’t generate revenue for a few years. ... But Lilium could fundamentally reshape the transportation industry,' Piper said.
A 0.7% increase in retail sales for August was unable to push the market higher even though analysts had been expecting a decline.
'Many of the macro factors driving overearning by [Avis Budget] in 2021 will likely persist well into 2022,' Bank of America says.